Anti-AKT (clone C67E7, #4691P, 1:1,000), anti-phospo-S473-AKT (clone D9E, #4060P, 1:1,000),
anti-AR (clone D6F11, #5153, 1:2,000), anti-HDAC1 (clone 10E2, #5356, 1:2,000), anti-γH2AX (clone 20E3, #9718, 1:2,000), anti-actin (clone 8H10D10, #3700, 1:4,000), anti-γErbB2 (clone Tyr1248, #2247, 1:1,000), and
anti-GAPDH (clone D16H11, #5174, 1:4,000–7,500) were from Cell Signalling Technology (Beverly, MA). Anti-HER2 (clone e2–4001, #MS730P0, 1:2,000) and anti-ER (clone AB-17, #RB1521PO, 1:1,500) were from Thermo Fisher (Waltham, MA). Anti-γDNP-PKcs (clone S2056, #18192, 1:1,000 was from Abcam (Cambridge, MA).
Enzalutamide was from Selleck (Houston, TX). DHT was from Steraloids (Newport, RI).
Yard B.D., Adams D.J., Chie E.K., Tamayo P., Battaglia J.S., Gopal P., Rogacki K., Pearson B.E., Phillips J., Raymond D.P., Pennell N.A., Almeida F., Cheah J.H., Clemons P.A., Shamji A., Peacock C.D., Schreiber S.L., Hammerman P.S, & Abazeed M.E. (2016). A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nature Communications, 7, 11428.